Imatinib Teva (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways that promote cell proliferation and survival, thereby inhibiting the expansion of cancerous cells that rely on these kinases.

The dosage of Imatinib Teva is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Imatinib is classified as contraindicated in pregnancy because it may cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while receiving imatinib, as the drug can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Imatinib Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer different potency or side‑effect profiles, but imatinib’s long‑term safety data and cost‑effectiveness make it a widely used choice.

Imatinib Teva should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Imatinib Teva is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious risks include hepatotoxicity, severe neutropenia or thrombocytopenia, cardiac failure, pulmonary arterial hypertension, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these events, and therapy should be discontinued if they occur.

Imatinib Teva is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should also be avoided in pregnant women and used with caution in individuals with severe hepatic impairment, significant cardiac disease, or uncontrolled infections.